Browse by Medical Category
Accepting New Patients
Dr. Lanuti is a board certified Thoracic Surgeon with special interest in lung cancer research, new techniques for lung cancer staging, and minimally invasive lung surgery.
Go To Programs
Go To Programs
Go To Specialties
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
After receiving a Bachelor of Science in BioEngineering from the University of Pennsylvania, Dr. Lanuti received his M.D. degree from the University of Pennsylvania School of Medicine . He completed his internship and residency in Surgery at the Hospital of the University of Pennsylvania and a two year research fellowship in a Thoracic Oncology Laboratory focusing on gene therapy for lung cancer. He continued with sub-specialty training, and finished a Cardiothoracic Fellowship at the Massachusetts General Hospital. He was recruited in 2004 to the staff of the Division of Thoracic Surgery, and holds a parallel appointment as Associate Professor of Surgery at Harvard Medical School. He has been the Friedman-Lambert Scholar in Academic Thoracic Surgery at MGH/HMS since 2004. He is the Director of Thoracic Oncology for the Division of Thoracic Surgery. Clinical interests include minimally invasive surgery for lung cancer, complex airway tumors, mediastinal tumors, esophageal cancer, navigation bronchoscopy, and surgery for hyperhidrosis.
Dr. Lanuti spearheads translational research in a Thoracic Oncology Research Laboratory. The principle goals of the laboratory are to design novel therapeutics to treat lung and esophageal cancer that can be brought to clinical trials. A primary goal is the use of oncolytic viruses to target solid tumor. Some of these strategies include development of oncolytic viruses that help degrade tumor matrix. Ultimately, this translational effort will strive to bring treatment strategies from the laboratory bench to the bedside and back to the bench again for re-evaluation and improvement.
Another lab interest is molecular imaging of pulmonary fibrosis. We have pioneered the first collagen-PET probe to be used in the quantitation of patients carrying a diagnosis of pulmonary fibrosis. This same technology will be used to better characterize radiation induced lung injury which may ultimately be used to help differentiate lung injury from tumor recurrence. Stage I non small cell lung cancer can still recur with a 25% chance of relapse despite complete resection. Dr. Lanuti is investigating the role of driver mutations and gene signatures to stratify risk of recurrence in resected stage I lung adenocarcinoma. This work can contribute to adjuvant therapies for high risk resected stage I lung cancers.
The study of epidermal growth factor and its influence on biologic functions, particularly the proliferation and differentiation of epithelial tissues, has received tremendous attention. Dr. Lanuti has investigated molecular risk factors for esophageal adenocarcinoma and found an elevated risk associated with single nucleotide polymorphisms in the epidermal growth factor (EGF) gene.
View my most recent publications at PubMed
45 doctors from Massachusetts General Hospital’s Department of Surgery included in Boston magazine's 2019 Top Doctors list.
Back to Top